. Sunitinib, SUTENT®) : inhibiteur de la tyrosine kinase des récepteurs PDGFR 2

K. Sorafenib, F. , and B. , NEXAVAR®): inhibiteur de la tyrosine kinase des récepteurs PDGFR

H. F. Dvorak, Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy, Journal of Clinical Oncology, vol.20, issue.21
DOI : 10.1200/JCO.2002.10.088

G. Zalcman, Biologie du cancer bronchique

A. Italiano and B. Bui, Aspects moléculaires et stratégies thérapeutiques des tumeurs stromales gastro-intestinales

L. Doucet, Définition, données récentes en anatomopathologie et biologie moléculaire des tumeurs stromales gastro-intestinales

K. D. Courtney, R. B. Corcoran, and J. A. Engelman, The PI3K Pathway As Drug Target in Human Cancer, Journal of Clinical Oncology, vol.28, issue.6
DOI : 10.1200/JCO.2009.25.3641

R. Roy, J. Yang, and M. A. Moses, Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer, Journal of Clinical Oncology, vol.27, issue.31
DOI : 10.1200/JCO.2009.23.5556

N. Pécuchet, T. Cluzeau, and C. Thibault, Inhibiteurs des histone-désacétylases : la régulation épigénétique sort de l'ombre

C. Gridelli, P. Maione, and D. Amoroso, Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting, Critical Reviews in Oncology/Hematology, vol.66, issue.2
DOI : 10.1016/j.critrevonc.2007.10.004

D. Marin, M. Dragana, and M. Bua, The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations, Clinical Leukemia, vol.1, issue.4
DOI : 10.3816/CLK.2007.n.013

G. Etienne, B. Milpied, and D. Réa, Recommandations du groupe Fi-LMC pour la gestion des effets indésirables du traitement par nilotinib (Tasigna®)

L. Morse and P. Calarese, EGFR-Targeted Therapy and Related Skin Toxicity, Seminars in Oncology Nursing, vol.22, issue.3
DOI : 10.1016/j.soncn.2006.04.005

R. Peréz-soler and L. Saltz, Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?, Journal of Clinical Oncology, vol.23, issue.22, pp.23-5235, 2005.
DOI : 10.1200/JCO.2005.00.6916

S. E. Dick and G. H. Crawford, Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors, Community Oncology, vol.2, issue.6, pp.492-96, 2005.
DOI : 10.1016/S1548-5315(11)70630-1

T. J. Lynch, J. , and E. S. Kim, Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management, The Oncologist, vol.12, issue.5
DOI : 10.1634/theoncologist.12-5-610

S. Tsimboukis, I. Merikas, and E. Karapanagiotou, Erlotinib-Induced Skin Rash in Patients with Non???Small-Cell Lung Cancer: Pathogenesis, Clinical Significance, and Management, Clinical Lung Cancer, vol.10, issue.2, pp.106-117, 2009.
DOI : 10.3816/CLC.2009.n.013

F. Guilhot, Indications for Imatinib Mesylate Therapy and Clinical Management, The Oncologist, vol.9, issue.3
DOI : 10.1634/theoncologist.9-3-271

. Eng-hooi-tan and A. Chan, Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors

L. C. Scott, J. D. White, and R. Reid, Management of skin toxicity related to the use of imatinib mesylate (STI571, GlivecTM) for advanced stage gastrointestinal stromal Tumours

E. Jabbour, M. Deininger, and A. Hochhaus, Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

C. Robert, Effets secondaires cutanés des molécules anti-angiogéniques

M. E. Lacouture, L. M. Reilly, and P. Gerami, Hand foot skin reaction in cancer patients treated wi th the multikinase inhibitors sorafenib and sunitinib

M. E. Lacouture, S. Wu, and C. Robert, Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib, The Oncologist, vol.13, issue.9
DOI : 10.1634/theoncologist.2008-0131

P. A. Wu, Y. Balagula, and M. E. Lacouture, Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors, Current Opinion in Oncology, vol.23, issue.4
DOI : 10.1097/CCO.0b013e3283474063

C. Robert and P. Gimel, Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : thérapies ciblées et effets secondaires dermatologiques

Y. Loriot, G. Perlemuter, and D. Malka, Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

B. Moy and P. Goss, Lapatinib-Associated Toxicity and Practical Management Recommendations, The Oncologist, vol.12, issue.7
DOI : 10.1634/theoncologist.12-7-756

V. Hirsh, Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer, Current Oncology, vol.18, issue.3
DOI : 10.3747/co.v18i3.877

J. Davin, P. Ducrotté, and N. Houédé, Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires digestifs

C. Porta, S. Osanto, and A. Ravaud, Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma, European Journal of Cancer, vol.47, issue.9
DOI : 10.1016/j.ejca.2011.02.014

S. Sonis, N. Treister, and S. Chawla, Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients, Cancer, vol.7, issue.14S
DOI : 10.1002/cncr.24696

N. Bhojani, C. Jeldres, and J. Patard, Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma, European Urology, vol.53, issue.5
DOI : 10.1016/j.eururo.2007.11.037

URL : https://hal.archives-ouvertes.fr/hal-00277571

A. Ravaud, Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies, The Oncologist, vol.16, issue.Supplement 2
DOI : 10.1634/theoncologist.2011-S2-32

K. Ho and J. Chiu, Multimodal antiemetic therapy and emetic risk profiling

R. Kumar, M. Crouthamel, and D. Rominger, Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors, British Journal of Cancer, vol.91, issue.10
DOI : 10.1038/nrc2559

E. Thanopoulou and I. Judson, The safety profile of imatinib in CML and GIST: long-term considerations, Archives of Toxicology, vol.10, issue.20465813
DOI : 10.1007/s00204-011-0729-7

F. Thibault, Aspects pratiques de la prescription du sunitinib, Progr??s en Urologie - FMC, vol.20, issue.1
DOI : 10.1016/j.fpurol.2009.12.001

J. Halimi, M. Azizi, and G. Bobrie, Effets vasculaires et r??naux des m??dicaments anti-angiog??niques: recommandations fran??aises pour la pratique, Oncologie, vol.49, issue.Suppl18S
DOI : 10.1007/s10269-009-1093-6

D. Keefe, J. Bowen, and R. Gibson, Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review, The Oncologist, vol.16, issue.4
DOI : 10.1634/theoncologist.2010-0271

C. Widakowich, D. Castro, and G. Jr, Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers, The Oncologist, vol.12, issue.12
DOI : 10.1634/theoncologist.12-12-1443

H. X. Chen and J. N. Cleck, Adverse effects of anticancer agents that target the VEGF pathway, Nature Reviews Clinical Oncology, vol.25, issue.8
DOI : 10.1038/nrclinonc.2009.94

D. White, P. Camus, and M. Endo, Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma, American Journal of Respiratory and Critical Care Medicine, vol.182, issue.3
DOI : 10.1164/rccm.200911-1720OC

A. Bergeron, D. Réa, and V. Levy, Lung abnormalities after dasatinib treatment for chronic myeloid leukemia a case series

D. Breilh, Pinguet F. Les bases de la réceptologie, 2008.

F. Penault-llorca, La participation des voies de signalisation dans l'oncogénèse

M. Glivec, Document du Laboratoire Novartis, Reuil-Malmaison, 2002.

A. Kahn and S. Gisselbrecht, Histoire de la thérapie ciblée en cancérologie, 2007.

A. Depierre, J. Lagrange, and T. S. , Cancer bronchopulmonaire non à petites cellules, 2002.

M. Talbert, G. Willoquet, and R. Gervais, Le guide pharmacoclinique, 2009.

U. Rosemont, Site web Weblo URL: http://www.weblo.com/website, 1144040.

. Accessible-en-pdf-À-l-'adresse-suivante, pdf [99] Recommendations for the management of Imatinib-resistant/intolerant chronic myeloid leukemia (CML) patients with the kinase inhibitor, SPRYCEL (Dasatinib) Accessible en pdf à l'adresse suivante : http://www.canadianhematologysociety.org/PDF-documents/Sprycel -Consensus.pdf [100] EGFR inhibitors: toxicities and strategies for effective management Accessible en pdf à l'adresse suivante, 2009.

. Loi, portant réforme de l'hôpital et relative aux patients, à la santé et aux territoires, J.O, vol.22, p.162, 2009.